IDENTIFICATION OF POTENTIAL DRUG-RELATED PROBLEMS (DRPS) AT PREECLAMPSIA AND ECLAMPSIA PATIENTS AT RSUP DR. HASAN SADIKIN BANDUNG
Preeclampsia and eclampsia are syndromes in pregnancy that cause morbidity and mortality therefore the appropriateness of therapy is needed. The high incidence of Drug Related Problems (DRPs) or drug-related problems can affect the unsuccess of therapy so this research needs to be done. The purp...
Saved in:
| Main Author: | |
|---|---|
| Format: | Theses |
| Language: | Indonesia |
| Online Access: | https://digilib.itb.ac.id/gdl/view/76386 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Institution: | Institut Teknologi Bandung |
| Language: | Indonesia |
| Summary: | Preeclampsia and eclampsia are syndromes in pregnancy that cause morbidity and
mortality therefore the appropriateness of therapy is needed. The high incidence of Drug
Related Problems (DRPs) or drug-related problems can affect the unsuccess of therapy
so this research needs to be done. The purpose of the study was to identify and assess the
incidence of potential drug-related problemsin preeclampsia and eclampsia patients with
or without comorbid diseases. The research conducted was a descriptive nonexperimental study with a cross-sectional design conducted retrospectively from medical
record data during the period January - December 2021. Sampling was carried out using
a non-probability sampling method, namely purposive sampling, with a total sample of
134 patients. The inclusion criteria of subjects are hospitalized patients with a diagnosis
of preeclampsia and eclampsia with or without comorbid diseases, while the exclusion
criteria are patients with incomplete or illegible medical records. Results of potential
DRPs showed as many as 36 cases (8.71%) of P.1 code of treatment effectiveness for
untreated symptoms or indications (P1.3). 109 cases (26.39%) code C.1 drug selection
for no drug indication (C1.3). 109 cases (26.39%) code C1.4 drug interactions. 101 cases
(24.45%) polypharmacy of code C1.7. 36 cases (8.71%) code C1.6 indicated untreated.
5 cases (1.21%) of drug code C1.1 do not match the guidelines. 2 cases (0.48%) of the
drug code C1.2 according to the guidelines but there are contraindications. 2 cases
(0.48%) code C1.5 duplication of the drug. 8 cases (1.93%) code C.3 dose selection for
excess drug dosage (C3.2). 5 cases (1,21%) code C3.1 dose of subtherapeutic drugs. The
results of bivariate analysis showed that age, gestational age, gestational status,
diagnosis, disease diagnosis, number of diagnoses, number of drugs, and length of stay
significantly increased the incidence of DRPs in patients (p < 0.05) and the results of
multivariate analysis using logistic regression showed a significant difference in
increasing the incidence of DRPs in patients with Omnibus Test (P) results (p < 0.05).
Results of potential DRPs showed 86 cases (3.53%) of magnesium sulfate with drug
interactions and 185 (22.07%) uses in therapy.
|
|---|